ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01451619
Recruitment Status : Completed
First Posted : October 13, 2011
Last Update Posted : March 25, 2015
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.